Digital health companies need GTM strategies built around clinical workflows, regulatory review, and multi-stakeholder buying committees. A SaaS playbook built for a single champion and a 30-day sales cycle breaks the moment it hits a health system's IT security and compliance queue.
The Problem
Clinical adoption cycles run on a different clock
Health systems and provider groups move slowly because clinical workflows are embedded in daily patient care and any disruption carries safety risk. Nurses and physicians need training time, EHR integration testing, and a change-management runway most digital health companies never budget for. GTM plans built around a typical 30-60 day SaaS sales cycle end up with stalled pilots that never convert to a signed contract.
The buying committee has five different scorecards
A digital health purchase touches clinical staff, hospital administration, IT security, legal and compliance, and often a board-level finance sign-off. Each group evaluates the product on a different axis – clinical outcomes, budget impact, data security, liability exposure – and a GTM motion built around one champion collapses when a second stakeholder asks a question the sales team can't answer.
Clinical evidence isn't optional, it's the entry ticket
Provider and payer buyers ask for peer-reviewed outcome data, clinical validation, or at minimum a documented pilot with real patient or workflow results before they'll sign. Companies that treat evidence generation as a post-launch marketing asset instead of a pre-sales requirement show up to committee reviews with nothing to hand the clinical lead who's asking for proof.
Regulatory review adds months to every deal
HIPAA compliance, FDA software-as-a-medical-device classification, state telehealth and data-residency rules, and hospital-specific security reviews (SOC 2, HITRUST) all sit in the critical path before a contract closes. GTM plans that don't build compliance documentation and security review prep into the sales process from day one lose deals in legal review after clinical buy-in is already won.
How We Help
We start with a market assessment specific to your clinical domain: how similar solutions have actually been adopted in your segment, who sits on the buying committee at your target accounts, and what regulatory classification applies to your product. This isn't generic healthcare research – it's a map of your specific sales ecosystem, from clinical champion to IT security sign-off, built to produce a realistic GTM timeline instead of a SaaS-speed one that sets false expectations internally.
Strategy comes next: a stakeholder-by-stakeholder plan that treats the clinical champion, the administrative buyer, IT security, and compliance as four separate audiences with four separate objections to pre-empt. We design the pilot program structure – scope, success metrics, and the path from pilot to signed contract – alongside a clinical evidence plan, because a pilot with no measurement framework produces goodwill but no proof.
On execution, we build the sales infrastructure your team actually uses: clinical champion development materials, security and compliance documentation packets ready before IT asks for them, and a customer success framework that turns your first hospital systems into references you can put in front of the next one. Healthcare GTM runs on trust transfer between institutions – a reference from one health system carries more weight with the next than any case study copy.
We close the loop with measurement: clinical outcome tracking tied to the metrics your buyers actually care about, win-loss analysis by stakeholder type, and a regulatory-landscape watch so your GTM plan adjusts as reimbursement codes or state telehealth rules shift under you.
What we deliver
- Clinical market and stakeholder map – who buys, who blocks, and what each one needs to see
- Multi-stakeholder GTM plan with regulatory and security-review prep built in, not bolted on
- Pilot program design with a measurement framework and a defined path to signed contract
- Clinical champion and reference-account development system
- Outcome tracking and win-loss analysis by stakeholder type
The digital health companies that scale aren't the ones with the best product demo – they're the ones whose clinical champion can defend the purchase in a room the vendor isn't in. GTM here is built around who advocates for you when you're not present, not around your pitch.
Our Methodology
Days 1-30 go into understanding your specific clinical market: how comparable products have actually been adopted or rejected in your segment, mapping the buying committee at your target accounts, and confirming what regulatory classification and security review your product will face. This phase ends with a GTM plan built on your real sales cycle length, not an assumed one.
Days 31-60 build the infrastructure: pilot program frameworks with defined success metrics, clinical evidence collection tied to those metrics, security and compliance documentation prepared ahead of IT's request instead of scrambled together after it, and sales materials written for each stakeholder type on the buying committee.
The final 30 days is launch and instrumentation – tracking clinical adoption and win-loss data by stakeholder, building the reference pipeline from early pilot accounts, and setting up the feedback loop that lets the GTM plan adjust as you learn what's actually working in market.
How We Work
The first two weeks are a market and stakeholder assessment: your current clinical relationships, existing pilot or evidence data, and where you sit on the regulatory/security review timeline. Weeks three and four turn that into a GTM plan and implementation roadmap.
Your team includes a GTM strategist with healthcare market experience, a regulatory specialist who tracks HIPAA, SaMD classification, and state telehealth rules, and a clinical adoption lead who's run change management inside health systems before. From your side we need access to clinical stakeholders, sales pipeline data, and any pilot results or evidence you've already generated – we don't manufacture proof, we build the plan around what's real.
Cadence is monthly strategy reviews with bi-weekly implementation check-ins, plus a written update each month covering stakeholder engagement, pipeline movement by buying-committee segment, and regulatory status changes that affect your timeline. Most clients see measurable improvement in stakeholder engagement and pipeline velocity within 8-10 weeks, with sales-cycle impact showing by week 12-16. Initial engagements run 4-6 months given how long healthcare sales cycles actually take to move.
- Faster clinical stakeholder alignment and shorter pilot-to-contract time
- Higher win rates once a deal reaches security and compliance review
- A working clinical evidence and reference pipeline instead of a one-off case study
- A GTM system that survives past the first health system, not one built around a single deal
If your digital health company needs go-to-market leadership, we should talk.
Expand your marketing team output with our experts
Let us take a custom approach to your growth goals by assembling and leading the best-in-class marketing team to support your next stage.
Frequently asked questions
How much does a GTM engagement cost for a digital health company?
Engagements typically run $25K-40K per month depending on how many buying-committee segments you're selling into and your regulatory complexity. That covers strategy, stakeholder-specific sales materials, and compliance/security prep work. It's a fraction of a full-time healthcare GTM hire with comparable experience, which usually runs $200K-plus in salary alone before you've built any of the supporting infrastructure.
How long before we see results from a healthcare GTM engagement?
Stakeholder engagement and pipeline movement typically improve within 8-10 weeks as the new sales process and materials go live. Measurable sales-cycle and win-rate impact usually shows up by week 12-16. Healthcare deals move slowly by nature, so full impact on closed revenue takes 6-9 months even when the underlying GTM work is solid.
How does your team work with our existing healthcare sales staff?
We work directly with your sales, clinical affairs, and customer success teams in regular working sessions, not as an outside layer they have to route around. Materials and process changes get built into your existing pipeline and CRM rather than living in a separate deck. We also train your team on stakeholder-specific objection handling, since that's usually the gap between a good pilot and a signed contract.
What makes Winston Francois different from a healthcare consulting firm?
Most healthcare consultants advise on clinical operations or hospital strategy, not on how a vendor sells software into a health system. We build GTM specifically for that sale – stakeholder mapping, evidence-backed pilots, and security review prep – because that's the actual bottleneck for digital health companies, not clinical operations advice.
How do you measure ROI on a healthcare GTM engagement?
We track pipeline velocity and win rate broken out by buying-committee segment, plus clinical adoption metrics tied to your pilot's own success criteria and reference-account growth. The goal is a repeatable sales motion that works on the fifth health system, not just a win on the first one. Most clients see a measurable shift in these numbers within 90-120 days.
What type of digital health company is the right fit for this?
Companies with real clinical value already proven in at least one pilot or early deployment, typically Series A-B with $5M-40M ARR, who are stuck converting pilots into signed, repeatable contracts. If you're still validating whether clinicians will use the product at all, that's a product problem to solve before GTM investment – not a fit for this engagement yet.
